{"nbformat":4,"nbformat_minor":0,"metadata":{"colab":{"provenance":[],"collapsed_sections":["pfKYDstK_njq","vw1jr09UbHiY","KtjeScws_hO5","fzuxkidegWyZ","UD6lq7Q0_ZMn","2avCKixIutVL","FUbOBZbLfqWK"],"authorship_tag":"ABX9TyOh5GQk2tNs0L52nXWmZgu/"},"kernelspec":{"name":"python3","display_name":"Python 3"},"language_info":{"name":"python"}},"cells":[{"cell_type":"markdown","source":["#HW1 - Clinical Trials Analytics in PySpark"],"metadata":{"id":"wPfjp4cHa3s7"}},{"cell_type":"markdown","source":["### 1. Spark Installation"],"metadata":{"id":"pfKYDstK_njq"}},{"cell_type":"markdown","source":["\n","Download and install Spark with all its dependencies"],"metadata":{"id":"vw1jr09UbHiY"}},{"cell_type":"code","execution_count":1,"metadata":{"id":"uC6WEZqlZzVC","executionInfo":{"status":"ok","timestamp":1744996253092,"user_tz":-120,"elapsed":60555,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}}},"outputs":[],"source":["#Install Java8\n","!apt-get install openjdk-8-jdk-headless -qq > /dev/null\n","\n","# download spark3.4.4\n","!wget -q https://apache.osuosl.org/spark/spark-3.4.4/spark-3.4.4-bin-hadoop3.tgz\n","\n","# unzip it\n","!tar xf spark-3.4.4-bin-hadoop3.tgz\n","\n","# install findspark\n","!pip install -q findspark"]},{"cell_type":"markdown","source":["It's necessary to add enviroment variables to make visible runtime Spark to linux enviroment. We could install different versions of spark and decide later which one we would use."],"metadata":{"id":"ef01lMs9b3fS"}},{"cell_type":"code","source":["import os\n","os.environ[\"JAVA_HOME\"] = \"/usr/lib/jvm/java-8-openjdk-amd64\"\n","os.environ[\"SPARK_HOME\"] = \"/content/spark-3.4.4-bin-hadoop3\""],"metadata":{"id":"yebiEf7Rcj8K","executionInfo":{"status":"ok","timestamp":1744996253095,"user_tz":-120,"elapsed":1,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}}},"execution_count":2,"outputs":[]},{"cell_type":"markdown","source":["You import the library `findspark` that allow to find and automatically initialize Spark configuration without having to manually configure enviroment variable and other options"],"metadata":{"id":"O2pNHomCdCrb"}},{"cell_type":"code","source":["import findspark\n","findspark.init()\n","\n","# Spark version verification on cluster\n","from pyspark.context import SparkContext\n","sc = SparkContext.getOrCreate()\n","\n","assert \"3.\" in sc.version, \"Verify that the cluster Spark's version is 3.x\""],"metadata":{"id":"k5cPMSp8egNU","executionInfo":{"status":"ok","timestamp":1744996263590,"user_tz":-120,"elapsed":10495,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}}},"execution_count":3,"outputs":[]},{"cell_type":"code","source":["sc"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":198},"id":"yFViaL7AgB4F","executionInfo":{"status":"ok","timestamp":1744996263612,"user_tz":-120,"elapsed":19,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"951f90c4-b159-47d2-a9b6-eeaa4618b605"},"execution_count":4,"outputs":[{"output_type":"execute_result","data":{"text/plain":["<SparkContext master=local[*] appName=pyspark-shell>"],"text/html":["\n","        <div>\n","            <p><b>SparkContext</b></p>\n","\n","            <p><a href=\"http://e1e2baa71d76:4040\">Spark UI</a></p>\n","\n","            <dl>\n","              <dt>Version</dt>\n","                <dd><code>v3.4.4</code></dd>\n","              <dt>Master</dt>\n","                <dd><code>local[*]</code></dd>\n","              <dt>AppName</dt>\n","                <dd><code>pyspark-shell</code></dd>\n","            </dl>\n","        </div>\n","        "]},"metadata":{},"execution_count":4}]},{"cell_type":"markdown","source":["### 2. Loading the Dataset on Spark"],"metadata":{"id":"KtjeScws_hO5"}},{"cell_type":"markdown","source":["\n","RDD is a data representation in Spark, but for simplicity of coding and design, it became necessary to introduce a new, more responsive data model.\n","\n","Spark SQL came to live, it offers to the users the opportunity ot use datasets/dataframes. They are objects tablelike: each column has a name and a type, each row is a combination of column values\n","\n","The SQL engine on Spark translates sql-like operations in RDDs and gives at the end a RDD with the results."],"metadata":{"id":"fzuxkidegWyZ"}},{"cell_type":"code","source":["# Libraries for SQL Spark\n","from pyspark.sql import SparkSession\n","from pyspark.sql import functions\n","from pyspark.sql.functions import split, explode, trim, count, sum, col, current_date, lower, regexp_replace\n","import time\n","\n","spark = SparkSession(sc)\n","print(spark)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"4gThEiXYk8mH","executionInfo":{"status":"ok","timestamp":1744996263971,"user_tz":-120,"elapsed":358,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"87406e36-3e1b-4234-e257-5850df6c318c"},"execution_count":5,"outputs":[{"output_type":"stream","name":"stdout","text":["<pyspark.sql.session.SparkSession object at 0x7d3351da9050>\n"]}]},{"cell_type":"markdown","source":["We can download the dataset from multiple sources (remote or local). Since it is a single csv file, not so big, let's download it on google drive enviroment, then mount the enviroment to the cluster file system"],"metadata":{"id":"SV8YcyvEnDeb"}},{"cell_type":"code","source":["from google.colab import drive\n","drive.mount('/content/drive')\n","\n","#Print all directories in my enviroment\n","print(os.listdir('/content/drive/MyDrive/Colab Notebooks/Big Data'))\n","\n","homework1Path = \"/content/drive/MyDrive/Colab Notebooks/Big Data/Homework 1\"\n","\n","#Save the path to the CSVs directory\n","csvPath = os.path.join(homework1Path,\"dimensions_clinicalTrials.csv\")\n","print(csvPath)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"ta-7MwNiljfA","executionInfo":{"status":"ok","timestamp":1744996289130,"user_tz":-120,"elapsed":25158,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"7103b03c-41ae-4873-c3e2-728082ecfa92"},"execution_count":6,"outputs":[{"output_type":"stream","name":"stdout","text":["Mounted at /content/drive\n","['Esercitazione Spark 25 03 2025', 'Esercitazione Hive 25 03 2025', 'Homework 1']\n","/content/drive/MyDrive/Colab Notebooks/Big Data/Homework 1/dimensions_clinicalTrials.csv\n"]}]},{"cell_type":"markdown","source":["Create the Dataset Object with the spark Object `read`"],"metadata":{"id":"6JFWVwbzpDya"}},{"cell_type":"code","source":["# Indentifies types for each column (float, integer, string, etc)\n","# Gets columns names of the first csv's row\n","ctDS = spark.read \\\n","  .option(\"inferSchema\", \"true\") \\\n","  .option(\"header\", \"true\") \\\n","  .option(\"multiline\", \"true\") \\\n","  .option(\"quote\", \"\\\"\") \\\n","  .option(\"escape\", \"\\\"\") \\\n","  .csv(csvPath)\n","\n","# Print the schema\n","ctDS.printSchema()"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"cdmmHuWDo7_w","executionInfo":{"status":"ok","timestamp":1744996303050,"user_tz":-120,"elapsed":13919,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"a5508a54-af8e-4b8e-ad3d-4bb8950c05ca"},"execution_count":7,"outputs":[{"output_type":"stream","name":"stdout","text":["root\n"," |-- Rank: integer (nullable = true)\n"," |-- Trial ID: string (nullable = true)\n"," |-- Title: string (nullable = true)\n"," |-- Brief title: string (nullable = true)\n"," |-- Acronym: string (nullable = true)\n"," |-- Abstract: string (nullable = true)\n"," |-- Start date: date (nullable = true)\n"," |-- Start Year: double (nullable = true)\n"," |-- End Date: date (nullable = true)\n"," |-- Completion Year: double (nullable = true)\n"," |-- Phase: string (nullable = true)\n"," |-- Study Type: string (nullable = true)\n"," |-- Study Design: string (nullable = true)\n"," |-- Conditions: string (nullable = true)\n"," |-- Recruitment Status: string (nullable = true)\n"," |-- Number of Participants: double (nullable = true)\n"," |-- Intervention: string (nullable = true)\n"," |-- Gender: string (nullable = true)\n"," |-- Age: string (nullable = true)\n"," |-- Registry: string (nullable = true)\n"," |-- Investigators/Contacts: string (nullable = true)\n"," |-- Sponsors/Collaborators: string (nullable = true)\n"," |-- City of Sponsor/Collaborator: string (nullable = true)\n"," |-- State of Sponsor/Collaborator: string (nullable = true)\n"," |-- Country of Sponsor/Collaborator: string (nullable = true)\n"," |-- Collaborating Funders: string (nullable = true)\n"," |-- Funder Group: string (nullable = true)\n"," |-- Funder Country: string (nullable = true)\n"," |-- Source Linkout: string (nullable = true)\n"," |-- Altmetric Attention Score: double (nullable = true)\n"," |-- Dimensions URL: string (nullable = true)\n"," |-- Fields of Research (ANZSRC 2020): string (nullable = true)\n"," |-- RCDC Categories: string (nullable = true)\n"," |-- HRCS HC Categories: string (nullable = true)\n"," |-- HRCS RAC Categories: string (nullable = true)\n"," |-- Cancer Types: string (nullable = true)\n"," |-- CSO Categories: string (nullable = true)\n"," |-- AHC: string (nullable = true)\n","\n"]}]},{"cell_type":"code","source":["# Let's print some rows\n","ctDS.select(\"*\").show(20, truncate = True)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"PWtHGDU5tBLX","executionInfo":{"status":"ok","timestamp":1744996306261,"user_tz":-120,"elapsed":3210,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"55f4ef4b-872c-42c1-8c71-c0445daefeca","collapsed":true},"execution_count":8,"outputs":[{"output_type":"stream","name":"stdout","text":["+----+--------------+--------------------+--------------------+-----------------+--------------------+----------+----------+----------+---------------+-------+--------------+--------------------+--------------------+--------------------+----------------------+--------------------+------+--------------------+------------------+----------------------+----------------------+----------------------------+-----------------------------+-------------------------------+---------------------+------------+--------------+--------------------+-------------------------+--------------------+--------------------------------+--------------------+--------------------+--------------------+--------------------+--------------------+---------------+\n","|Rank|      Trial ID|               Title|         Brief title|          Acronym|            Abstract|Start date|Start Year|  End Date|Completion Year|  Phase|    Study Type|        Study Design|          Conditions|  Recruitment Status|Number of Participants|        Intervention|Gender|                 Age|          Registry|Investigators/Contacts|Sponsors/Collaborators|City of Sponsor/Collaborator|State of Sponsor/Collaborator|Country of Sponsor/Collaborator|Collaborating Funders|Funder Group|Funder Country|      Source Linkout|Altmetric Attention Score|      Dimensions URL|Fields of Research (ANZSRC 2020)|     RCDC Categories|  HRCS HC Categories| HRCS RAC Categories|        Cancer Types|      CSO Categories|            AHC|\n","+----+--------------+--------------------+--------------------+-----------------+--------------------+----------+----------+----------+---------------+-------+--------------+--------------------+--------------------+--------------------+----------------------+--------------------+------+--------------------+------------------+----------------------+----------------------+----------------------------+-----------------------------+-------------------------------+---------------------+------------+--------------+--------------------+-------------------------+--------------------+--------------------------------+--------------------+--------------------+--------------------+--------------------+--------------------+---------------+\n","| 100|   NCT05817903|Phase II Study of...|Axitinib Intensif...|             AxIn|This phase II ope...|2023-04-18|    2023.0|2027-04-01|         2027.0|Phase 2|Interventional|Allocation: Rando...|Metastatic Renal ...|          Recruiting|                 118.0|Axitinib (Drug), ...|   All|      18 Years - N/A|ClinicalTrials.gov|  Roberto Iacovelli...|  Consorzio Oncotec...|        Naples; New York;...|         ; New York; ; ; ;...|           Italy; United Sta...| Pfizer (United St...|        null| United States|https://clinicalt...|                     null|https://app.dimen...|            32 Biomedical and...|Clinical Research...|                null| 6.1 Pharmaceuticals|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT05482490|A Novel Hygienic ...|Maintenance Proto...|             null|The study we inte...|2022-10-01|    2022.0|2023-12-31|         2023.0|   null|Interventional|Allocation: N/A; ...|   Implant Infection|  Not yet recruiting|                 130.0|Maintenance proto...|   All|           N/A - N/A|ClinicalTrials.gov|                  null|  University of Cag...|          Cagliari; Cagliari|                            ;|                   Italy; Italy| University of Cag...|        null|         Italy|https://clinicalt...|                     null|https://app.dimen...|            32 Biomedical and...|Bioengineering; C...|           Infection|                null|                null|                null|AOUSSN_CAGLIARI|\n","| 100|ISRCTN44988547|The 3TR Molecular...|Are RNA signature...|3TR Precis-The-RA|Background and st...|2022-09-20|    2022.0|2026-09-01|         2026.0|Phase 4|Interventional|Allocation: Rando...|Rheumatoid arthritis|                null|                 240.0|                null|   All|         None - None|            ISRCTN|  Liliane Fossati-J...|  Queen Mary Univer...|        London; ; London;...|         ; ; ; ; ; ; Bruss...|           United Kingdom; ;...| Queen Mary Univer...|        null|United Kingdom|https://www.isrct...|                     null|https://app.dimen...|            32 Biomedical and...|Autoimmune Diseas...|Inflammatory and ...| 6.1 Pharmaceuticals|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT05242484|A Phase 2b Random...|A Study of Combin...|          DUET-UC|The purpose of th...|2022-09-19|    2022.0|2029-02-28|         2029.0|Phase 2|Interventional|Allocation: Rando...| Colitis, Ulcerative|          Recruiting|                 550.0|Guselkumab (Biolo...|   All| 18 Years - 65 Years|ClinicalTrials.gov|                  null|  Janssen (United S...|        Hopewell; Arcadia...|         New Jersey; Calif...|           United States; Un...| Johnson & Johnson...|        null| United States|https://clinicalt...|                     null|https://app.dimen...|            32 Biomedical and...|Clinical Research...|Oral and gastroin...| 6.1 Pharmaceuticals|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT05481580|Relationship Betw...|Restorations and ...|             null|The aim of this s...|2022-09-01|    2022.0|2023-06-30|         2023.0|   null| Observational|Observational Mod...|   Furcation Defects|  Not yet recruiting|                 200.0|Periodontal probi...|   All|           N/A - N/A|ClinicalTrials.gov|                  null|  University of Cag...|          Cagliari; Cagliari|                            ;|                   Italy; Italy| University of Cag...|        null|         Italy|https://clinicalt...|                     null|https://app.dimen...|            32 Biomedical and...|      Bioengineering|                null|                null|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT05481567|Oral Health Relat...|Periodontitis Sta...|             null|Patients diagnose...|2022-09-01|    2022.0|2023-06-30|         2023.0|   null| Observational|Observational Mod...|       Periodontitis|  Not yet recruiting|                 100.0|Questionnaire (Ot...|   All|           N/A - N/A|ClinicalTrials.gov|                  null|  University of Cag...|          Cagliari; Cagliari|                            ;|                   Italy; Italy| University of Cag...|        null|         Italy|https://clinicalt...|                     null|https://app.dimen...|            32 Biomedical and...|Prevention; Pain ...|Oral and gastroin...|                null|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT05472233|The Effect of Sut...|Effect of Suturin...|             null|The purpose of th...|2022-09-01|    2022.0|2022-12-31|         2022.0|   null|Interventional|Allocation: Non-R...|  Gingival Recession|  Not yet recruiting|                  20.0|Suture removal af...|   All|           N/A - N/A|ClinicalTrials.gov|  Nicola Alberto Va...|  University of Cag...|          Cagliari; Cagliari|                            ;|                   Italy; Italy| University of Cag...|        null|         Italy|https://clinicalt...|                     null|https://app.dimen...|            32 Biomedical and...|Dental/Oral and C...|                null|                null|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT05242471|A Phase 2b Random...|A Study of Combin...|          DUET-CD|The purpose of th...|2022-07-22|    2022.0|2030-10-08|         2030.0|Phase 2|Interventional|Allocation: Rando...|     Crohn's Disease|          Recruiting|                 715.0|Guselkumab (Biolo...|   All| 18 Years - 65 Years|ClinicalTrials.gov|                  null|  Janssen (United S...|        Hopewell; Birming...|         New Jersey; Alaba...|           United States; Un...| Johnson & Johnson...|        null| United States|https://clinicalt...|                     null|https://app.dimen...|            32 Biomedical and...|Clinical Research...|                null| 6.1 Pharmaceuticals|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT05198934|A Phase 3 Multice...|Sotorasib and Pan...|     CodeBreak300|The aim of the st...|2022-04-19|    2022.0|2025-03-12|         2025.0|Phase 3|Interventional|Allocation: Rando...|Colorectal Cancer...|Active, not recru...|                 160.0|Sotorasib (Drug),...|   All|18 Years - 100 Years|ClinicalTrials.gov|                  null|  Amgen (United Sta...|        Thousand Oaks; Bi...|         California; Alaba...|           United States; Un...| Amgen (United Sta...|        null| United States|https://clinicalt...|                     10.0|https://app.dimen...|            32 Biomedical and...|Cancer; Clinical ...|              Cancer| 6.1 Pharmaceuticals|Colon and Rectal ...|5.4 Systemic Ther...|AOUSSN_CAGLIARI|\n","| 100|   NCT05943951|Lymphadenectomy i...|Italian Study on ...|          CoDIG-2|The objective of ...|2022-04-01|    2022.0|2022-10-30|         2022.0|   null| Observational|Observational Mod...|Colon Cancer; Lym...|           Completed|                 788.0|Right hemicolecto...|   All| 18 Years - 95 Years|ClinicalTrials.gov|       Gabriele Anania|  Gabriele Anania; ...|        ; Jesi; Acquaviva...|         ; Ancona; Bari; B...|           ; Italy; Italy; I...|                 null|        null|          null|https://clinicalt...|                     null|https://app.dimen...|            32 Biomedical and...|Clinical Research...|                null|         6.4 Surgery|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT05052801|A Randomized, Mul...|Bemarituzumab or ...|    FORTITUDE-101|The main objectiv...|2022-03-07|    2022.0|2025-08-18|         2025.0|Phase 3|Interventional|Allocation: Rando...|Gastric Cancer; G...|          Recruiting|                 516.0|Bemarituzumab (Dr...|   All|18 Years - 100 Years|ClinicalTrials.gov|                  null|  Amgen (United Sta...|        Thousand Oaks; ; ...|         California; ; Ala...|           United States; ; ...| Amgen (United Sta...|        null| United States|https://clinicalt...|                      1.0|https://app.dimen...|            32 Biomedical and...|Clinical Trials a...|              Cancer| 6.1 Pharmaceuticals|      Stomach Cancer|5.4 Systemic Ther...|AOUSSN_CAGLIARI|\n","| 100|   NCT05320250|Raman Spectroscop...|Saliva and Extrac...|           RaSPiD|Rehabilitation is...|2021-12-15|    2021.0|2024-12-31|         2024.0|   null| Observational|Observational Mod...|Parkinson's Disea...|          Recruiting|                 180.0|Single saliva col...|   All| 50 Years - 85 Years|ClinicalTrials.gov|  Alice Gualerzi; M...|  Fondazione Don Ca...|        ; ; Cagliari; Mil...|                      ; ; ; ;|           ; ; Italy; Italy;...|                 null|        null|          null|https://clinicalt...|                      1.0|https://app.dimen...|            4201 Allied Healt...|Neurodegenerative...|        Neurological|4.1 Discovery and...|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT05071664|A Phase 2a, Multi...|A Study of Guselk...|         AFFINITY|The purpose of th...|2021-10-25|    2021.0|2024-08-13|         2024.0|Phase 2|Interventional|Allocation: Rando...|Arthritis, Psoriatic|Active, not recru...|                  92.0|Guselkumab (Drug)...|   All| 18 Years - 65 Years|ClinicalTrials.gov|                  null|  Janssen (United S...|        Hopewell; Phoenix...|         New Jersey; Arizo...|           United States; Un...| Johnson & Johnson...|        null| United States|https://clinicalt...|                     27.0|https://app.dimen...|            32 Biomedical and...|Rare Diseases; Cl...|Inflammatory and ...|6.1 Pharmaceutica...|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT04929210|A Phase 4, Multic...|A Study of Guselk...|             STAR|The purpose of th...|2021-08-30|    2021.0|2026-02-13|         2026.0|Phase 4|Interventional|Allocation: Rando...|Arthritis, Psoriatic|          Recruiting|                 405.0|Guselkumab (Drug)...|   All|      18 Years - N/A|ClinicalTrials.gov|                  null|  Janssen (United S...|        Hopewell; Chandle...|         New Jersey; Arizo...|           United States; Un...| Johnson & Johnson...|        null| United States|https://clinicalt...|                    131.0|https://app.dimen...|            32 Biomedical and...|Rare Diseases; Cl...|Inflammatory and ...| 6.1 Pharmaceuticals|Not Site-Specific...|5.4 Systemic Ther...|AOUSSN_CAGLIARI|\n","| 100|   NCT04763408|A Multicentre, Ob...|A Study to Evalua...|          STELLAR|The primary purpo...|2021-04-09|    2021.0|2028-03-31|         2028.0|   null| Observational|Observational Mod...|Carcinoma, Hepato...|          Recruiting|                1000.0|Lenvatinib (Drug)...|   All|      18 Years - N/A|ClinicalTrials.gov|                  null|  Eisai (Japan); Un...|        Tokyo; San Franci...|         ; California; Cal...|           Japan; United Sta...|        Eisai (Japan)|        null|         Japan|https://clinicalt...|                    299.0|https://app.dimen...|            32 Biomedical and...|Patient Safety; D...|                null| 6.1 Pharmaceuticals|        Liver Cancer|5.4 Systemic Ther...|AOUSSN_CAGLIARI|\n","| 100|   NCT04755569|Clinical Investig...|Optimizer System ...|             null|The objective of ...|2021-03-01|    2021.0|2025-12-31|         2025.0|   null| Observational|Observational Mod...|Evaluate the Safe...|          Recruiting|                 200.0|ODOCOR II CCM LEA...|   All|      18 Years - N/A|ClinicalTrials.gov|  Stefano DeVivo; S...|  Impulse Dynamics ...|        Orangeburg; Heilb...|         New York; Baden W...|           United States; Ge...|                 null|        null|          null|https://clinicalt...|                     null|https://app.dimen...|            32 Biomedical and...|Bioengineering; A...|      Cardiovascular|                null|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT04524611|A Phase 3, Multic...|Study Comparing I...|         SEQUENCE|Crohn's disease (...|2020-09-30|    2020.0|2028-02-11|         2028.0|Phase 3|Interventional|Allocation: Rando...|Crohn's Disease (CD)|Active, not recru...|                 527.0|Risankizumab (Dru...|   All| 18 Years - 80 Years|ClinicalTrials.gov|            ABBVIE INC|  AbbVie (United St...|        North Chicago; Ch...|         Illinois; Arizona...|           United States; Un...| AbbVie (United St...|        null| United States|https://clinicalt...|                      4.0|https://app.dimen...|            32 Biomedical and...|Clinical Trials a...|Oral and gastroin...| 6.1 Pharmaceuticals|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT04303780|A Phase 3 Multice...|Study to Compare ...|             null|A Phase 3 Study t...|2020-06-04|    2020.0|2026-04-27|         2026.0|Phase 3|Interventional|Allocation: Rando...|KRAS p, G12c Muta...|Active, not recru...|                 345.0|AMG 510 (Drug), D...|   All|18 Years - 100 Years|ClinicalTrials.gov|                  null|  Amgen (United Sta...|        Thousand Oaks; An...|         California; Calif...|           United States; Un...| Amgen (United Sta...|        null| United States|https://clinicalt...|                    788.0|https://app.dimen...|            32 Biomedical and...|Cancer; Lung; Cli...|              Cancer| 6.1 Pharmaceuticals|         Lung Cancer|5.4 Systemic Ther...|AOUSSN_CAGLIARI|\n","| 100|   NCT04175613|A Phase 3b, Multi...|A Long-term Exten...|             null|This study was cr...|2019-12-20|    2019.0|2027-02-22|         2027.0|Phase 3|Interventional|Allocation: N/A; ...|           Psoriasis|Active, not recru...|                 160.0|   Apremilast (Drug)|   All|  6 Years - 17 Years|ClinicalTrials.gov|                  null|  Amgen (United Sta...|        Thousand Oaks; Ph...|         California; Arizo...|           United States; Un...| Amgen (United Sta...|        null| United States|https://clinicalt...|                      1.0|https://app.dimen...|            32 Biomedical and...|Clinical Research...|                null| 6.1 Pharmaceuticals|                null|                null|AOUSSN_CAGLIARI|\n","| 100|   NCT04102007|A Phase 3b, Multi...|A Study of the Sa...|             null|This study will e...|2019-11-12|    2019.0|2022-11-07|         2022.0|Phase 3|Interventional|Allocation: N/A; ...|    Plaque Psoriasis|           Completed|                 244.0| Risankizumab (Drug)|   All|      18 Years - N/A|ClinicalTrials.gov|            ABBVIE INC|  AbbVie (United St...|        North Chicago; Ph...|         Illinois; Arizona...|           United States; Un...| AbbVie (United St...|        null| United States|https://clinicalt...|                      7.0|https://app.dimen...|            32 Biomedical and...|Emerging Infectio...|                Skin| 6.1 Pharmaceuticals|                null|                null|AOUSSN_CAGLIARI|\n","+----+--------------+--------------------+--------------------+-----------------+--------------------+----------+----------+----------+---------------+-------+--------------+--------------------+--------------------+--------------------+----------------------+--------------------+------+--------------------+------------------+----------------------+----------------------+----------------------------+-----------------------------+-------------------------------+---------------------+------------+--------------+--------------------+-------------------------+--------------------+--------------------------------+--------------------+--------------------+--------------------+--------------------+--------------------+---------------+\n","only showing top 20 rows\n","\n"]}]},{"cell_type":"markdown","source":["### 3. Preprocessing"],"metadata":{"id":"UD6lq7Q0_ZMn"}},{"cell_type":"markdown","source":["\n","At a first sight it could not be clear, but in this dataset there are a lot of duplicate rows. Clean the dataset with dropDuplicates()\n","\n"],"metadata":{"id":"2avCKixIutVL"}},{"cell_type":"code","source":["# Dirty Dataset\n","count_dirty = ctDS.count()\n","\n","# Cleaned Dataset\n","#ctDS = ctDS.fillna(\"NA_TEMP\")\n","ctDS = ctDS.dropDuplicates([\"Trial ID\"])\n","#ctDS = ctDS.replace(\"NA_TEMP\", None)\n","count_clean = ctDS.count()\n","\n","print(\"Dirty: \" + str(count_dirty))\n","print(\"Clean: \" + str(count_clean))\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"GXjfNtETuuLU","executionInfo":{"status":"ok","timestamp":1744996332799,"user_tz":-120,"elapsed":5543,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"c94fdec3-d565-4e5d-d819-dbfbf10939b6"},"execution_count":9,"outputs":[{"output_type":"stream","name":"stdout","text":["Dirty: 15990\n","Clean: 8356\n"]}]},{"cell_type":"code","source":["# Before the cleaning there were 7 rows with this \"title\"\n","ctDS.select(\"*\").where(ctDS[\"Title\"] == \"Phase III Study on STem cElls Mobilization in Acute Myocardial Infarction\").show(20,truncate=False)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"collapsed":true,"id":"-SUFj--qll0y","executionInfo":{"status":"ok","timestamp":1744996344026,"user_tz":-120,"elapsed":8322,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"8d8473ff-039a-487c-f4bf-5d2ad384a7b6"},"execution_count":10,"outputs":[{"output_type":"stream","name":"stdout","text":["+----+-----------+-------------------------------------------------------------------------+--------------------------------------------------------------------+--------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------+----------+----------+---------------+-------+--------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------+------------------+----------------------+---------------------------+------+-------------------+------------------+-------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------+------------+--------------+-------------------------------------------+-------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------+-------------------------------+--------------------+--------------+-----------+\n","|Rank|Trial ID   |Title                                                                    |Brief title                                                         |Acronym |Abstract                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |Start date|Start Year|End Date  |Completion Year|Phase  |Study Type    |Study Design                                                                                                           |Conditions                                                                 |Recruitment Status|Number of Participants|Intervention               |Gender|Age                |Registry          |Investigators/Contacts         |Sponsors/Collaborators                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |City of Sponsor/Collaborator                                                                                                                                                                                                                                                                                                                                                                                                                                                             |State of Sponsor/Collaborator                                                                                                                  |Country of Sponsor/Collaborator                                                                                                                                                                                                                                                                                                                                                      |Collaborating Funders|Funder Group|Funder Country|Source Linkout                             |Altmetric Attention Score|Dimensions URL                                              |Fields of Research (ANZSRC 2020)                                                 |RCDC Categories                                                                                                                                                                                                                               |HRCS HC Categories|HRCS RAC Categories            |Cancer Types        |CSO Categories|AHC        |\n","+----+-----------+-------------------------------------------------------------------------+--------------------------------------------------------------------+--------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------+----------+----------+---------------+-------+--------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------+------------------+----------------------+---------------------------+------+-------------------+------------------+-------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------+------------+--------------+-------------------------------------------+-------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------+-------------------------------+--------------------+--------------+-----------+\n","|100 |NCT01969890|Phase III Study on STem cElls Mobilization in Acute Myocardial Infarction|STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial|STEM-AMI|The purpose of this study is to demonstrate that granulocyte colony-stimulating factor (G-CSF) therapy in addition to state-of-the-art treatment (pharmacological and non pharmacological) is safe and significantly improves clinical outcome in patients with reduced left ventricular ejection fraction (LVEF) (≤45%) after successful reperfusion for large anterior acute myocardial infarction.\\n\\nDetailed Description\\nPost infarction heart failure (HF) remains a major cause of morbidity and mortality. In the United States, more than three million patients, and 700.000 in Italy, have cardiac failure and its most common cause is ischemic heart disease. The major goal to improve post infarction LV function would be the stimulation of neovascularization and the enhancement of regeneration of cardiac myocytes within the infarcted area. Recent experimental studies suggest that bone marrow-derived progenitor cells (BMCs) or circulating endothelial progenitor cells (cEPCs) contribute to the regeneration of infarcted myocardium, to enhance neovascularization of ischemic myocardium, to prevent cardiomyocyte apoptosis, to alter scar formation by reducing the development of myocardial fibrosis and, thereby, to improve cardiac function.G-CSF is a hematopoietic cytokine produced by monocytes, fibroblasts and endothelial cells. G-CSF is known to have multiple functions in normal, steady-state hematopoiesis. It is routinely used to mobilize CD34+ hematopoietic stem cells from the BM into peripheral blood, thus enabling their easier collection compared to BM aspirate procedure. The proven efficacy and safety of G-CSF, both in healthy donors and patients with haematological disease, along with favourable results from studies of CD34+ cell transplantation in patients with MI or ischemia, suggest that G-CSF based BMC transplantation may have an efficacy in patients with MI.|2013-10-01|2013.0    |2018-05-01|2018.0         |Phase 3|Interventional|Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment|Anterior Acute Myocardial Infarction; Left Ventricular Systolic Dysfunction|Terminated        |532.0                 |G-CSF administration (Drug)|All   |18 Years - 75 Years|ClinicalTrials.gov|Felice Achilli; Giulio Pompilio|Heart Care Foundation; A. Manzoni Hospital; Centro Cardiologico Monzino; Azienda Ospedaliero Universitaria Ospedali Riuniti; Ospedale Generale Provinciale CG Mazzoni - Divisione di Cardiologia; Ospedale San Donato; AORN Giuseppe Moscati - UO Cardiologia-UTIC; Humanitas Gavazzeni; Azienda Ospedaliera Bolognini Seriate; Ospedale Maggiore Carlo Alberto Pizzardi; Ospedale Sant'Elia - Cardiologia-UTIC; Moriggia Pelascini Hospital; Ospedale Sant'Anna - UOC Cardiologia; Azienda Ospedaliera Ospedale Maggiore; Istituti Ospitalieri di Cremona; Azienda Ospedaliero-Universitaria Careggi; Ospedale Policlinico San Martino; Ospedale Misericordia di Grosseto; Presidio Ospedaliero; Alessandro Manzoni Hospital; Ospedale Campo Marte - UO Cardiologia; Ospedale di Circolo e Fondazione Macchi; Azienda Ospedaliera San Gerardo; Ospedale Bassini; Azienda Ospedaliera di Desio e Vimercate; Azienda Ospedaliera Fatebenefratelli e Oftalmico; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Cardiologico Monzino; Ospedale San Paolo; Ospedale San Luca - Centro Auxologico - UO Cardiologia; Azienda Ospedaliera Ospedale San Carlo Borromeo; Luigi Sacco Hospital; Ospedale Niguarda Ca' Granda; IRCCS Humanitas Research Hospital; Presidio Ospedaliero Carlo Poma - UO Cardiologia; Ospedale San Francesco - Cardiologia UTIC; Ospedale Giovanni Paolo II - UTIC Cardiologia; Ospedaliera di Piacenza; Azienda Ospedaliera di Padova; AOU Pisana - UO Malattie Cardiovasc. 1-Cisanello; Policlinico San Matteo Fondazione; Arcispedale Santa Maria Nuova - UO Degenza Cardiologica; AO San Giovanni Addolorata - Cardiologia 2; Ospedale Infermi di Rimini; AOUS Giovanni Di Dio Ruggi D'Aragona - UOC UTIC; Azienda Ospedaliero Universitaria San Giovanni Battista; Ospedale di Cattinara; Ca' Foncello Hospital; Ospedale di Circolo di Busto Arsizio; Presidio Ospedaliero di Saronno - UOC Cardiologia; Ospedale dell' Angelo; Ospedale di Belcolle; Ospedale Antonio Cardarelli; University of Naples Federico II; AO Univ. Maggiore della Carità - Cardiologia 2|; ; Milan; Ancona; Ascoli Piceno; Arezzo; Avellino; Bergamo; Seriate; Bologna; Caltanissetta; Gravedona; San Fermo della Battaglia; Crema; Cremona; Florence; Genoa; Grosseto; Lavagna; Lecco; Lucca; Varese; Monza; Milan; Desio; Milan; Milan; Milan; Milan; Milano; Milan; Milan; Milan; Rozzano; Mantova; Nuoro; Olbia; Piacenza; Padova; Pisa; Pavia; Reggio Emilia; Roma; Rimini; Salerno; Turin; Trieste; Treviso; Busto Arsizio; Saronno; Venice; Viterbo; Naples; Naples; Novara|; ; ; ; AP; ; AV; ; ; ; CL; ; CO; ; ; ; ; ; ; ; LU; ; ; ; ; ; ; ; ; MI; ; ; ; ; MN; NU; OT; ; ; PI; ; RE; RM; ; SA; ; ; ; ; VA; ; ; ; Campania;|; ; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy; Italy|null                 |null        |null          |https://clinicaltrials.gov/show/NCT01969890|1.0                      |https://app.dimensions.ai/details/clinical_trial/NCT01969890|32 Biomedical and Clinical Sciences; 3201 Cardiovascular Medicine and Haematology|Transplantation; Heart Disease; Stem Cell Research - Nonembryonic - Non-Human; Clinical Research; Regenerative Medicine; Cardiovascular; Stem Cell Research - Nonembryonic - Human; Heart Disease - Coronary Heart Disease; Stem Cell Research|Cardiovascular    |5.2 Cellular and gene therapies|Leukemia / Leukaemia|null          |AOU_CAREGGI|\n","+----+-----------+-------------------------------------------------------------------------+--------------------------------------------------------------------+--------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------+----------+----------+---------------+-------+--------------+-----------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------+------------------+----------------------+---------------------------+------+-------------------+------------------+-------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------+------------+--------------+-------------------------------------------+-------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------+-------------------------------+--------------------+--------------+-----------+\n","\n"]}]},{"cell_type":"markdown","source":["There's still something wrong...Some columns have pseudo-structured data, like dictionaries and lists. In particular:\n","\n","**Dictionaries**\n","\n","*   Study Design\n","\n","**Lists**\n","\n","*   Conditions\n","*   Investigators/Contacts\n","*   Sponsors/Collaborators\n","*   City of Sponsor/Collaborator\n","*   State of Sponsor/Collaborator\n","*   Country of Sponsor/Collaborator\n","*   Fields of Research (ANZSRC 2020)\n","*   RCDC Categories\n","*   HRCS HC Categories\n","*   HRCS RAC Categories\n","*   Cancer Types\n","*   CSO Categories\n","\n","For better analytics, we have changed manually the type of these columns with a preprocessing script.\n","\n","\n"],"metadata":{"id":"fAk0T_NHuNuX"}},{"cell_type":"code","source":["from pyspark.sql.functions import expr\n","\n","# All columns that are pseudo-lists\n","columnsList = [\"Conditions\",\"Investigators/Contacts\",\"Sponsors/Collaborators\",\"City of Sponsor/Collaborator\",\"State of Sponsor/Collaborator\",\"Country of Sponsor/Collaborator\",\"Fields of Research (ANZSRC 2020)\",\"RCDC Categories\",\"HRCS HC Categories\",\"HRCS RAC Categories\",\"Cancer Types\",\"CSO Categories\"]\n","\n","# Cicle for all lists\n","for column in columnsList:\n","  ctDS = ctDS.withColumn(\n","      column,\n","      # Wiht expr function, we use sql like preprocessing\n","      expr(f\"\"\"\n","        transform(\n","            split(`{column}`, ';'),\n","            x -> CASE WHEN trim(x) = '' THEN NULL ELSE trim(x) END\n","        )\n","      \"\"\"\n","    )\n","  )\n","\n"],"metadata":{"collapsed":true,"id":"F_drxKEFRmsd","executionInfo":{"status":"ok","timestamp":1744996350839,"user_tz":-120,"elapsed":1078,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}}},"execution_count":11,"outputs":[]},{"cell_type":"code","source":["# For the only Dictionary\n","ctDS = ctDS.withColumn(\n","  \"Study Design\",\n","  expr(\"\"\"\n","    map_from_entries(\n","            transform(\n","                split(`Study Design`, ';'),\n","                entry -> struct(\n","                    trim(split(entry, ':')[0]) as key,\n","                    IF(size(split(entry, ':')) > 1, trim(split(entry, ':')[1]), NULL) as value\n","                )\n","            )\n","        )\n","  \"\"\")\n",")"],"metadata":{"id":"fMUsVwEQdxAp","executionInfo":{"status":"ok","timestamp":1744996352893,"user_tz":-120,"elapsed":264,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}}},"execution_count":12,"outputs":[]},{"cell_type":"code","source":["ctDS.select(\"Conditions\").show(100,truncate = False)\n","#ctDS.select(col(\"Conditions\")[0].alias(\"first_condition\")).show(truncate = False)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"k-Z5SKUJclIy","executionInfo":{"status":"ok","timestamp":1744997009015,"user_tz":-120,"elapsed":2618,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"cadddc92-0a90-415c-fd49-7ee80adbf139"},"execution_count":23,"outputs":[{"output_type":"stream","name":"stdout","text":["+--------------------------------------------+\n","|Conditions                                  |\n","+--------------------------------------------+\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Chronic myeloid leukaemia]                 |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Epilepsy]                                  |\n","|[Colorectal cancer NOS]                     |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Pregnancy induced hypertension]            |\n","|null                                        |\n","|[Multiple sclerosis]                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Gastroenteritis helicobacter]              |\n","|null                                        |\n","|[Intractable epilepsy]                      |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Colorectal adenocarcinoma]                 |\n","|null                                        |\n","|[Colon cancer metastatic]                   |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Multiple myelomas]                         |\n","|[Congenital, familial and genetic disorders]|\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Hyperhomocysteinaemia]                     |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Non-small cell lung cancer]                |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Renal cancer metastatic]                   |\n","|null                                        |\n","|[Prostate cancer metastatic]                |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Biliary neoplasm]                          |\n","|[Nervous system disorders]                  |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","|[Maculopathy]                               |\n","|[Rectal cancer]                             |\n","|null                                        |\n","|null                                        |\n","|null                                        |\n","+--------------------------------------------+\n","only showing top 100 rows\n","\n"]}]},{"cell_type":"code","source":["#ctDS.select(\"Study Design\").show(truncate = False)\n","ctDS.select(col(\"Study Design\")[\"Allocation\"].alias(\"Allocation_type\")).show(truncate = False)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"nyMqEnFKd2RB","executionInfo":{"status":"ok","timestamp":1744996359879,"user_tz":-120,"elapsed":2019,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"4337b6c7-8020-4530-efe0-7b2c7a849621"},"execution_count":14,"outputs":[{"output_type":"stream","name":"stdout","text":["+---------------+\n","|Allocation_type|\n","+---------------+\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","|null           |\n","+---------------+\n","only showing top 20 rows\n","\n"]}]},{"cell_type":"markdown","source":["### 4. Analytics"],"metadata":{"id":"FUbOBZbLfqWK"}},{"cell_type":"code","source":["# Save all the results in csv format\n","\n","# create the new repo path\n","resultsPath = os.path.join(homework1Path,\"results\")"],"metadata":{"id":"-0u-cXNQguQk","executionInfo":{"status":"ok","timestamp":1744996361752,"user_tz":-120,"elapsed":2,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}}},"execution_count":15,"outputs":[]},{"cell_type":"code","source":["# Number of studies started per year\n","studiesPerYear = ctDS.select(\"Start Year\") \\\n","  .filter(ctDS[\"Start Year\"].isNotNull()) \\\n","  .groupBy(ctDS[\"Start Year\"]) \\\n","  .count() \\\n","  .withColumnRenamed(\"count\",\"NumStudies per Year\") \\\n","  .orderBy(col(\"NumStudies per Year\").desc())\n","\n","studiesPerYear.show(50,truncate = False)\n","\n","# Saving result in a csv\n","studiesPerYearResult = studiesPerYear.toPandas()\n","studiesPerYearResult.to_csv(os.path.join(resultsPath,\"studiesPerYear.csv\"))\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"ORn1JhiVf0pH","executionInfo":{"status":"ok","timestamp":1744996372874,"user_tz":-120,"elapsed":8824,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"2664b3fb-2f51-45c0-d231-a06e5206cea4","collapsed":true},"execution_count":16,"outputs":[{"output_type":"stream","name":"stdout","text":["+----------+-------------------+\n","|Start Year|NumStudies per Year|\n","+----------+-------------------+\n","|2021.0    |722                |\n","|2020.0    |661                |\n","|2019.0    |640                |\n","|2018.0    |589                |\n","|2022.0    |585                |\n","|2017.0    |548                |\n","|2015.0    |457                |\n","|2016.0    |446                |\n","|2023.0    |399                |\n","|2014.0    |397                |\n","|2013.0    |370                |\n","|2012.0    |367                |\n","|2011.0    |325                |\n","|2010.0    |295                |\n","|2009.0    |287                |\n","|2008.0    |287                |\n","|2007.0    |226                |\n","|2006.0    |200                |\n","|2005.0    |130                |\n","|2004.0    |101                |\n","|2003.0    |56                 |\n","|2001.0    |45                 |\n","|2002.0    |40                 |\n","|2024.0    |38                 |\n","|2000.0    |35                 |\n","|1998.0    |19                 |\n","|1999.0    |18                 |\n","|1997.0    |11                 |\n","|1995.0    |8                  |\n","|1996.0    |8                  |\n","|1994.0    |7                  |\n","|1993.0    |4                  |\n","|1992.0    |3                  |\n","|1988.0    |2                  |\n","|2025.0    |2                  |\n","|1987.0    |1                  |\n","|1989.0    |1                  |\n","|1991.0    |1                  |\n","+----------+-------------------+\n","\n"]}]},{"cell_type":"code","source":["# Average number of participants per study title\n","\n","# Check if the title column is unique, maybe the question is refering title type\n","tot_rows = ctDS.count()\n","\n","distinct_rows = ctDS.select(\"Title\").distinct().count()\n","\n","if tot_rows == distinct_rows:\n","  print(\"They're the same\")\n","else:\n","  print(\"They're NOT the same\")\n","\n","# As shown they aren't the same, so we can group by title\n","print(\"Tot_rows: \" + str(tot_rows))\n","print(\"Distinct_rows: \" + str(distinct_rows))"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"4Chr9heWhzhQ","executionInfo":{"status":"ok","timestamp":1744996386334,"user_tz":-120,"elapsed":4851,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"a2e27908-7d40-4ce1-ad73-b5b84b499e4d"},"execution_count":17,"outputs":[{"output_type":"stream","name":"stdout","text":["They're NOT the same\n","Tot_rows: 8356\n","Distinct_rows: 8334\n"]}]},{"cell_type":"code","source":["# Check which Title is duplicated, but the trials are different\n","duplicates = ctDS.groupBy(\"Title\") \\\n","  .count() \\\n","  .filter(col(\"count\") > 1)\n","\n","duplicates.select(\"Title\",\"count\").show(truncate=False)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"-6Q7s7K_qvnm","executionInfo":{"status":"ok","timestamp":1744996423901,"user_tz":-120,"elapsed":2547,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"eb204b06-82be-44fd-cee2-6023960afe20"},"execution_count":18,"outputs":[{"output_type":"stream","name":"stdout","text":["+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----+\n","|Title                                                                                                                                                                                                                                                                        |count|\n","+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----+\n","|SAlute e LaVoro in Chirurgia Oncologica (SALVO)                                                                                                                                                                                                                              |2    |\n","|non disponibile                                                                                                                                                                                                                                                              |2    |\n","|SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions                                                                                                                  |2    |\n","|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication                                                 |2    |\n","|A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration                                   |2    |\n","|A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients|2    |\n","|Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery                                                                                                                                                                             |2    |\n","|A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis                                                                                                             |2    |\n","|A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions                                                                                                                                  |2    |\n","|NGR018: Randomized Phase II Study of NGR-hTNF Plus an Anthracycline Versus an Anthracycline Alone in Platinum-resistant Ovarian Cancer                                                                                                                                       |2    |\n","|A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis                                                                                                                               |2    |\n","|A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease                                           |2    |\n","|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria                                                 |2    |\n","|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis                                               |2    |\n","|Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance                                                                                                                       |2    |\n","|Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma                                                                                                                                                                                         |2    |\n","|A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMANIZED ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA                                                                                 |2    |\n","|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease                                                                             |2    |\n","|Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano: Dalla Disbiosi Alla Simbiosi                                                                                                                                                                        |4    |\n","|A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis                                                     |2    |\n","+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----+\n","\n"]}]},{"cell_type":"code","source":["from pyspark.sql.functions import avg\n","\n","# Average number of participants per study title\n","averagePerTitle = ctDS.select(\"Title\",\"Number of Participants\") \\\n","  .filter(ctDS[\"Title\"].isNotNull()) \\\n","  .groupBy(\"Title\") \\\n","  .agg(avg(\"Number of Participants\").alias(\"Average per Title\")) \\\n","  .orderBy(col(\"Average per Title\").desc())\n","\n","averagePerTitle.show(20,truncate=False)\n","\n","averagePerTitleResult = averagePerTitle.toPandas()\n","averagePerTitleResult.to_csv(os.path.join(resultsPath,\"averagePerTitle.csv\"))\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"bG6XYI_tlUx4","executionInfo":{"status":"ok","timestamp":1744997342257,"user_tz":-120,"elapsed":6764,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"bbed383c-ebe3-43a6-bf43-ccb2b6eaeeb4"},"execution_count":24,"outputs":[{"output_type":"stream","name":"stdout","text":["+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+\n","|Title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |Average per Title|\n","+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+\n","|The epidemiology, severity, and outcomes of children presenting to emergency departments across Europe during the SARS-COV-2 pandemic: the EPISODES study                                                                                                                                                                                                                                                                                                                                                                                     |2400000.0        |\n","|ACCESS template protocol for safety of COVID-19 vaccines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |1000000.0        |\n","|National Database of the Virtual Institute of Cerebrovascular Diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |285600.0         |\n","|Computerized Registry of Patients With Venous Thromboembolism (RIETE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |120000.0         |\n","|Effect of Pharmacist Involvement on Patient Reporting of Adverse Drug Reactions: A Multiregional Italian Study                                                                                                                                                                                                                                                                                                                                                                                                                                |115000.0         |\n","|CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |105000.0         |\n","|Digital Strategies in Primary Cardiovascular Prevention in the Italian Population                                                                                                                                                                                                                                                                                                                                                                                                                                                             |82800.0          |\n","|RICALOR - Registro Italiano Complicanze Anestesia LOco Regionale - Italian Registry for Complications During Regional Anesthesia                                                                                                                                                                                                                                                                                                                                                                                                              |63692.0          |\n","|What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |60000.0          |\n","|Analysis of In-hospital Acute Kidney Injury Epidemiology, Treatment and Outcomes                                                                                                                                                                                                                                                                                                                                                                                                                                                              |60000.0          |\n","|Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection)                                                                                                                                                                                                                                                                                                             |60000.0          |\n","|HPV as Primary Screening Test in Cervical Cancer Prevention: From DNA to mRNA? A Randomised Controlled Trial Nested in a Double Testing Study With Long Term Follow up                                                                                                                                                                                                                                                                                                                                                                        |60000.0          |\n","|International Randomized Study Comparing Personalized, Risk-Stratified to Standard Breast Cancer Screening In Women Aged 40-70                                                                                                                                                                                                                                                                                                                                                                                                                |53142.0          |\n","|PRospective Evaluation of the European Society of Cardiology 0/1-hour Algorithm's Safety and Efficacy for Triage of Patients With Suspected Myocardial Infarction (PRESC1SE-MI)                                                                                                                                                                                                                                                                                                                                                               |52156.0          |\n","|DianaWeb: Before and After Study Online Based Participatory Research to Test Whether Lifestyle and Diet Are Able to Reduce the Incidence of Recurrences (Local, Remote) or Secondary Cancers, Improve Prognosis and Survival of Breast Cancer                                                                                                                                                                                                                                                                                                 |50000.0          |\n","|A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease                                                                                                                                                                                                                                                                                                                                                               |39480.0          |\n","|Evaluation and Improvement of the Health-care Quality in Semi-intensive Care Units                                                                                                                                                                                                                                                                                                                                                                                                                                                            |39000.0          |\n","|Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)                                                                                                                                                                                                                                                                                                                                                                                                                                                      |35921.0          |\n","|Antibiotic Prophylaxis for Cataract Surgery Version 7e January 22 2003                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |35000.0          |\n","|ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.|31546.0          |\n","+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+\n","only showing top 20 rows\n","\n"]}]},{"cell_type":"code","source":["# Top 10 most frequent medical conditions\n","ctDS.select(explode(ctDS[\"Conditions\"]).alias(\"Condition\")) \\\n","  .filter(col(\"Condition\").isNotNull()) \\\n","  .groupBy(\"Condition\") \\\n","  .count() \\\n","  .withColumnRenamed(\"count\",\"Count per Condition\") \\\n","  .orderBy(col(\"Count per Condition\").desc()) \\\n","  .limit(10).show(truncate=False)"],"metadata":{"id":"SQ2TH9vwofpc","colab":{"base_uri":"https://localhost:8080/"},"executionInfo":{"status":"ok","timestamp":1744997953064,"user_tz":-120,"elapsed":2191,"user":{"displayName":"Salvatore Cangiano","userId":"12290973697877667813"}},"outputId":"deaeed4e-d050-4fd6-8cd9-feef6a02ac77"},"execution_count":28,"outputs":[{"output_type":"stream","name":"stdout","text":["+-----------------------+-------------------+\n","|Condition              |Count per Condition|\n","+-----------------------+-------------------+\n","|Breast Cancer          |157                |\n","|Multiple Myeloma       |83                 |\n","|Coronary Artery Disease|71                 |\n","|Heart Failure          |62                 |\n","|Ovarian Cancer         |60                 |\n","|Lung Cancer            |60                 |\n","|Colorectal Cancer      |56                 |\n","|Ulcerative Colitis     |52                 |\n","|Melanoma               |51                 |\n","|Prostate Cancer        |47                 |\n","+-----------------------+-------------------+\n","\n"]}]}]}